OBJECTIVES: Multiple studies have shown that the expression level of Homeobox (HOX) transcript antisense RNA (HOTAIR) has a correlation with the diagnosis and prognosis of acute leukemia (AL) and lymphoma. The prognostic significance of HOTAIR on AL and lymphoma has been controversial. Our study thus was performed to further reveal its prognostic value in leukemia and lymphoma. METHODS: By literature searching in some common electronic databases, five studies covering a number of 531 patients were included in this meta-analysis. We extracted useful data to calculate the pooled hazard ratio (HR) and p-value. RESULTS: The combined HR estimated for overall survival (OS) was 1.87 (95% confidence interval (CI): 1.03-3.47; p = .041) when comparing patients with high HOTAIR with those low. For event/disease/relapse-free survival, the HR was 1.53 (95%CI: 0.58-4.06; p = .39). Subgroup analyses showed that the HR for OS was 2.32 (95%CI: 1.56-3.44; p = .000) in patients with AL and 1.24 (95%CI: 0.21-7.45; p = .817) in lymphoma. Additionally, the Ann-Arbor stage (p = .0009) and the international prognostic index score (p = .0065) were found to be statistically significant between patients with high and low HOTAIR expression. Also, the hemoglobin (HGB) level (p = .008), platelet (PLT) count (p = .001) and blasts in bone marrow (p = .001), but not the French-American-British classification, were found statistically significant. DISCUSSION: Although our analysis has its limitation, it showed that high expression of HOTAIR had a significantly inferior impact on OS and some clinical parameter of leukemia and lymphoma patients. CONCLUSION: HOTAIR played an important prognostic role in leukemia and lymphoma and might serve as a potential target for therapeutic intervention in those patients.
OBJECTIVES: Multiple studies have shown that the expression level of Homeobox (HOX) transcript antisense RNA (HOTAIR) has a correlation with the diagnosis and prognosis of acute leukemia (AL) and lymphoma. The prognostic significance of HOTAIR on AL and lymphoma has been controversial. Our study thus was performed to further reveal its prognostic value in leukemia and lymphoma. METHODS: By literature searching in some common electronic databases, five studies covering a number of 531 patients were included in this meta-analysis. We extracted useful data to calculate the pooled hazard ratio (HR) and p-value. RESULTS: The combined HR estimated for overall survival (OS) was 1.87 (95% confidence interval (CI): 1.03-3.47; p = .041) when comparing patients with high HOTAIR with those low. For event/disease/relapse-free survival, the HR was 1.53 (95%CI: 0.58-4.06; p = .39). Subgroup analyses showed that the HR for OS was 2.32 (95%CI: 1.56-3.44; p = .000) in patients with AL and 1.24 (95%CI: 0.21-7.45; p = .817) in lymphoma. Additionally, the Ann-Arbor stage (p = .0009) and the international prognostic index score (p = .0065) were found to be statistically significant between patients with high and low HOTAIR expression. Also, the hemoglobin (HGB) level (p = .008), platelet (PLT) count (p = .001) and blasts in bone marrow (p = .001), but not the French-American-British classification, were found statistically significant. DISCUSSION: Although our analysis has its limitation, it showed that high expression of HOTAIR had a significantly inferior impact on OS and some clinical parameter of leukemia and lymphomapatients. CONCLUSION:HOTAIR played an important prognostic role in leukemia and lymphoma and might serve as a potential target for therapeutic intervention in those patients.
Authors: Didier Ismael May-Hau; Diego Alberto Bárcenas-López; Juan Carlos Núñez-Enríquez; Vilma Carolina Bekker-Méndez; Fredy Omar Beltrán-Anaya; Elva Jiménez-Hernández; Mónica Patricia Ortíz-Maganda; Francisco Xavier Guerra-Castillo; Aurora Medina-Sanson; Janet Flores-Lujano; Jorge Alfonso Martín-Trejo; José Gabriel Peñaloza-González; Martha Margarita Velázquez-Aviña; José Refugio Torres-Nava; Gabriela Alicia Hernández-Echáurregui; Rosa Martha Espinosa-Elizondo; María de Lourdes Gutiérrez-Rivera; Rodrigo Sanchez-Hernandez; María Luisa Pérez-Saldívar; Luz Victoria Flores-Villegas; Laura Elizabeth Merino-Pasaye; David Aldebarán Duarte-Rodríguez; Minerva Mata-Rocha; Omar Alejandro Sepúlveda-Robles; Haydeé Rosas-Vargas; Alfredo Hidalgo-Miranda; Juan Manuel Mejía-Aranguré; Silvia Jiménez-Morales Journal: Front Oncol Date: 2022-06-02 Impact factor: 5.738
Authors: Sara Kashani; Hosein Ali Sasan; Gholamreza Bahari; Behrouz Mollashahi; Seyed Mehdi Hashemi; Mohsen Taheri Journal: Asian Pac J Cancer Prev Date: 2021-09-01